Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4757714 | 0.79 | CYP2D6 (0.35) | SMN1; SMN2CYP2D6CYP2C19 | |
| SCHEMBL4316264 | 0.74 | SMN1; SMN2 (0.33) | SMN1; SMN2 | |
| SCHEMBL29094108 | 0.71 | TP53 (0.41) | SMN1; SMN2ATMCYP2D6 | |
| SCHEMBL2494718 | 0.67 | PIK3CD (0.36) | SMN1; SMN2ATMCYP2D6CYP2C19 | |
| SCHEMBL2488711 | 0.67 | PIK3CD (0.36) | SMN1; SMN2ATMCYP2D6CYP2C19 | |
| SCHEMBL28972346 | 0.66 | ATM (0.30) | ATM | |
| SCHEMBL14931661 | 0.64 | CARM1 (0.31) | — | |
| SCHEMBL25621670 | 0.64 | CYP2D6 (0.42) | CYP2D6CYP2C19 | |
| SCHEMBL25621672 | 0.64 | CYP2D6 (0.42) | CYP2D6CYP2C19 | |
| SCHEMBL25621678 | 0.64 | CYP2D6 (0.42) | CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9593128-B2 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | HOFFMANN-LA ROCHE INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-20150191487-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | GENENTECH, INC. (US) | 2015-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150191487-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX2, P2RX5 | SMN1; SMN2 2345/4885ATM 3488/4885CYP2D6 1512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.